Animerra is a pioneering company in the field of veterinary biologics, dedicated to developing innovative therapeutics for companion animals. Utilizing a unique discovery platform, Animerra combines advanced protein modalities to target areas previously deemed unreachable in veterinary medicine. Their mission is to tackle critical health challenges in companion animals by focusing on chronic pain, fibrosis-driven diseases, and allergic conditions, thereby filling significant gaps left by traditional biologics.

The company’s proprietary technology enhances drug discovery through ultra-high-diversity mRNA display libraries and artificial intelligence, enabling it to identify unique therapeutic targets and improve treatment outcomes. Animerra’s experienced leadership team has a rich background in protein discovery, biologics manufacturing, and regulatory processes, ensuring robust development from concept to market.

Partnered with Anterra Capital, Animerra is poised to advance the standard of care in veterinary medicine by offering safe, effective, and conveniently dosed therapeutics. Their commitment to companion animal health promises to improve the quality of life for pets and their owners.